alzohis.com rapport :   Visitez le site

Données techniques du alzohis.com

Geo IP vous fournit comme la latitude, la longitude et l'ISP (Internet Service Provider) etc. informations. Notre service GeoIP a trouvé l'hôte alzohis.com.Actuellement, hébergé dans France et son fournisseur de services est Dedibox SAS .

the related websites

domaine	Titre
alzohis.com	alzohis - simple blood test for alzheimer and other neurodegenerative disease
blood-arena.ru	[blood arena] cs 1.6 portal - cs 1.6 - 1.6 blood-arena e - nosteam count
blood-ownership.xyz	blood-ownership.xyz - blood-ownership resources and information.
simpltek.com	water testing made simple – diy water test kits
testcolor.com	testcolor | free color personality test, mood test, love test.
tests-qi.com	qi, test qi, test de qi, test personnalit, test intelligence
lesimplegoutdeschoses.fr	le simple goût des choses | cuisiner au plus simple pour le meilleur
bazarmagazin.com	Simple comme un chili con carne - La Cuisine cest simple
test-adn.fr	faire un test adn ou un test de paternité | test-adn.fr
bloodvale.com	the valley of the river of blood...
bgdiet.info	blood glucose diets
rubberdollies.com	blue blood's rubber dollies
cord-blood-eua.info	ebook cord-blood-eua.info
bbbl.fr	blood bowl baston league
testvihrapide.com	auto-test depistage vih | acheter test vih rapide - test vih rapide

parisbiotech.org umr-cnrs8612.u-psud.fr fr.news.yahoo.com formation.gref-bretagne.com coujinti.com tutorials-newsgroup.com les-crises.fr recettedebase.com tictone.com latourbrette.com francocube.com 

Analyse d'en-tête HTTP

Les informations d'en-tête HTTP font partie du protocole HTTP que le navigateur d'un utilisateur envoie à appelé nginx contenant les détails de ce que le navigateur veut et acceptera de nouveau du serveur Web.

DNS

HtmlToText

toggle navigation home about services patients physicians more biologists research applications news team partners faq contacts language english français alzohis a better diagnosis for a better medical management. the first blood test for patients suffering from mild cognitive impairments - a novel test to diagnose alzheimer and other neurodegenerative diseases - a test soon available on medical prescription or for clinical research. the first reliable and non-invasive test of alzheimer's disease. a test to assist patient cohort selection and monitoring of clinical trials to test new drug candidates. some words about us alzohis is a young innovative biotechnology company created in 2014. 2016 - hadrien peltier about alzohis our philosophy alzohis provides a new molecular diagnostic test for alzheimer’s disease. a novel combination of biomarkers leading to a typical “signature” detectable in the blood. this signature is able to discriminate patients suffering from alzheimer’s disease (ad) from healthy ones and from other neurodegenerative diseases. alzohis, a new tool for physicians. this diagnosis is based among others on the measure of specific blood biomarkers. today this type of score, based on a computational model, is relatively well accepted by the medical community (business model identical to diagnosis of trisomy 21, hepatitis c ...). alzheimer's disease is so common that it is currently an issue of global general interest. it also affects the family of sufferers, putting them under intense psychological, social and financial pressure. we need an earlier diagnosis, in order to provide better care! alzohis has expertises in : (i)biomolecular analysis, (ii) development of algorithms, (iii) management of big data in a secure environment. alzohis has the ambition to provide a revolutionary diagnostic tools to help neurologists and specialists to secure their diagnosis. this disease is detected very late, on average 3-4 years after the first symptoms. alzohis develops the first reliable non-invasive molecular diagnostic method. it's clear now that alzheimer's begins decades before symptoms start and that the best treatments will likely begin early, before there is too much damage to reverse. the development of new curative treatments of ad is strongly correlated to the conception of earlier and more specific diagnoses. biomolecular-based diagnostic methods currently available for alzheimer’s disease are still insufficient in terms of precocity and performances. this slows the development of new pharmaceutical molecules with curative intent. how does it work? simple : non-invasive solutions 1 - the doctor prescribes the physician prescribes the alzohis test when his patient presents cognitive impairments or clinical symptoms. 2 - go to the laboratory as soon as possible, the patient goes to a medical laboratory close to his home for a standard blood test 3 - a simple blood test the analysis is performed by the laboratory. less than one hour is required. 4 - results are sent the laboratory or the physician connects through a secured connection with the alzohis platform and sends the blood test results. 5 - get alzohis's score the alzohis tests are calculated in our secured environment, using our powerful algorithms. 6 - diagnosis proposed the result sheet listing all the relevant information is immediately available for the doctor. you are a patient discovered in 1906 by aloïs alzheimer, alzheimer's disease is a brain disorder. it leads to a progressive loss of neurons. the moment when the diagnosis is made during the patient’s life. three different diagnoses were considered, represented by a patient p, “early patient” diagnosed at mild stage, a patient m, “average patient” diagnosed at the start of the moderate stage and a patient t, “late patient” diagnosed at the end of the moderate stage. you are a physician we provide revolutionary diagnostic tools to help neurologists and specialists to better secure your diagnosis. alzheimer's disease is a major medical problem, with a prevalence in the developed countries of more than 1%, which greatly increases with age. it is clear now that alzheimer's disease begins decades before symptoms start and that the best treatments will likely begin early before there is too much damage to reverse. the current diagnostic strategies for alzheimer's disease are still inadequate in terms of precocity and performances, slowing considerably the development of new pharmaceutical molecules with a curative intent. 2016 - alain verpillot you are a biologist the determination of plasma mono-amine levels is of clinical importance in the diagnosis of some tumors of the nervous system. the plasma concentrations of metabolites may then be several times above the upper reference limits. also for scientific questions in the area of stress research and in sports, medicine mono-amines levels provide useful information. for pharmacological functional tests, it is necessary to measure plasma levels. the quantitative determination of blood metabolites is not only useful in differential diagnoses of hypertension but also for the evaluation of a number of other clinical and pharmacological aspects. the concentrations of these are indicative for the activity of the sympathetic nervous system, and are important parameters in congestive cardiac insufficiency, coronary heart disease, diabetes mellitus, arteriosclerosis, acute asthma, and others. clinical research for biotech strategies and analytical methods are available for medical laboratories. better diagnosis for better treatment : the development of new curative treatments of ad is strongly linked to the conception of earlier and more specific diagnoses. diagnostic methods currently available for alzheimer’s disease and based on biochemical analyzes are still insufficient. this slows the development of new pharmaceutical molecules with curative possibilities. 2016 - alain verpillot 47 million patients have dementia in the world 9.9 million new cases of dementia in 2015 50 % patients were never diagnosed 28800 new cases of dementia each day in the world simple and effective ways to distinguish dementia disruptive innovation in the diagnosis for patient suffuring from neurodegenerative diseases neurodegenerative diseases and dementia neurodegeneration is the umbrella term for the progressive loss of structure or functions of neurons, including the death of neurons. many neurodegenerative diseases including amyotrophic lateral sclerosis, parkinson's or alzheimer's disease, progressive supranuclear palsy and frontotemporal lobar degeneration occur as a result of neurodegenerative processes. such diseases are incurable, resulting in progressive degeneration and/or the death of neuron cells. alzheimer (ad) the most common early symptom is the difficulty to remember recent events (short-term memory loss). as the disease progresses, symptoms can include problems with language, disorientation (including getting lost easily), mood swings, loss of motivation, not managing self care, and behavioural issues. as a person's condition declines, this person often withdraws from family and society. gradually, bodily functions are lost, ultimately leading to death. approximately 1 people per 100 population have ad. amyotrophic lateral sclerosis (als) is a specific disorder that involves the death of neurons. als is characterized bystiff muscles, muscle twitching, and gradually worsening weakness due to muscles decreasing in size. this results in difficulty speaking, swallowing, and eventually breathing. approximately 2.5 people per 100,000 population have als. parkinson's disease (pd) also known as idiopathic or primary parkinsonism, hypokinetic rigid syndrome, or paralysis agitans, is adegenerative disorder of the central nervous systemmainly affecting the motor system. the motor symptoms of parkinson's disease result from the death of dopamine-generating cells in thesubstantianigra, a region of the

Analyse PopURL pour alzohis.com

https://www.alzohis.com/en/#about
https://www.alzohis.com/en/#physician
https://www.alzohis.com/en/#team
https://www.alzohis.com/en/#patient
https://www.alzohis.com/en/#faq
https://www.alzohis.com/en/#dropdown
https://www.alzohis.com/en/#tab_2
https://www.alzohis.com/en/en/
https://www.alzohis.com/en/#tab_1
https://www.alzohis.com/en/#services
https://www.alzohis.com/en/#collapsethree
https://www.alzohis.com/en/#research
https://www.alzohis.com/en/img/portfolio/world_alzheimer_report_2015_full.png
https://www.alzohis.com/en/#collapsefour
https://www.alzohis.com/en/#contacts
iledefrance.fr
cnrs.fr
hec.fr
hopital-saintlouis.aphp.fr
bpifrance.fr
u-psud.fr
umr-cnrs8612.u-psud.fr
reseau-entreprendre-paris.fr
chu-montpellier.fr
dim-analytics.fr

Informations Whois

Whois est un protocole qui permet d'accéder aux informations d'enregistrement.Vous pouvez atteindre quand le site Web a été enregistré, quand il va expirer, quelles sont les coordonnées du site avec les informations suivantes. En un mot, il comprend ces informations;

Domain Name: ALZOHIS.COM
Registry Domain ID: 1840034390_DOMAIN_COM-VRSN
Registrar WHOIS Server: whois.gandi.net
Registrar URL: http://www.gandi.net
Updated Date: 2016-11-03T15:11:25Z
Creation Date: 2013-12-22T18:34:20Z
Registry Expiry Date: 2017-12-22T18:34:20Z
Registrar: Gandi SAS
Registrar IANA ID: 81
Registrar Abuse Contact Email: abuse@support.gandi.net
Registrar Abuse Contact Phone: +33.170377661
Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited
Name Server: A.DNS.GANDI.NET
Name Server: B.DNS.GANDI.NET
Name Server: C.DNS.GANDI.NET
DNSSEC: unsigned
URL of the ICANN Whois Inaccuracy Complaint Form: https://www.icann.org/wicf/
>>> Last update of whois database: 2017-10-19T11:01:06Z <<<

For more information on Whois status codes, please visit https://icann.org/epp

NOTICE: The expiration date displayed in this record is the date the
registrar's sponsorship of the domain name registration in the registry is
currently set to expire. This date does not necessarily reflect the expiration
date of the domain name registrant's agreement with the sponsoring
registrar. Users may consult the sponsoring registrar's Whois database to
view the registrar's reported date of expiration for this registration.

TERMS OF USE: You are not authorized to access or query our Whois
database through the use of electronic processes that are high-volume and
automated except as reasonably necessary to register domain names or
modify existing registrations; the Data in VeriSign Global Registry
Services' ("VeriSign") Whois database is provided by VeriSign for
information purposes only, and to assist persons in obtaining information
about or related to a domain name registration record. VeriSign does not
guarantee its accuracy. By submitting a Whois query, you agree to abide
by the following terms of use: You agree that you may use this Data only
for lawful purposes and that under no circumstances will you use this Data
to: (1) allow, enable, or otherwise support the transmission of mass
unsolicited, commercial advertising or solicitations via e-mail, telephone,
or facsimile; or (2) enable high volume, automated, electronic processes
that apply to VeriSign (or its computer systems). The compilation,
repackaging, dissemination or other use of this Data is expressly
prohibited without the prior written consent of VeriSign. You agree not to
use electronic processes that are automated and high-volume to access or
query the Whois database except as reasonably necessary to register
domain names or modify existing registrations. VeriSign reserves the right
to restrict your access to the Whois database in its sole discretion to ensure
operational stability. VeriSign may restrict or terminate your access to the
Whois database for failure to abide by these terms of use. VeriSign
reserves the right to modify these terms at any time.

The Registry database contains ONLY .COM, .NET, .EDU domains and
Registrars.

  REGISTRAR Gandi SAS

SERVERS

  SERVER com.whois-servers.net

  ARGS domain =alzohis.com

  PORT 43

  TYPE domain
RegrInfo
DOMAIN

  NAME alzohis.com

  CHANGED 2016-11-03

  CREATED 2013-12-22

STATUS
clientTransferProhibited https://icann.org/epp#clientTransferProhibited

NSERVER

  A.DNS.GANDI.NET 173.246.98.1

  B.DNS.GANDI.NET 213.167.229.1

  C.DNS.GANDI.NET 217.70.179.1

  REGISTERED yes

Erreurs

La liste suivante vous montre les fautes d'orthographe possibles des internautes pour le site Web recherché.